benzyl 2-chloro-4-hydroxybenzoate | 115168-73-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl 2-chloro-4-hydroxybenzoate
• 英文别名: 2-chloro-4-hydroxybenzoic acid benzyl ester
• CAS: 115168-73-5
• 化学式: C₁₄H₁₁ClO₃
• 分子量: 262.693
• InChiKey: UKQPTEWFNZEMCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  benzyl 2-chloro-4-hydroxybenzoate 在 palladium 10% on activated carbon 氢气 、 caesium carbonate 、 sodium iodide 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 13.42h， 生成 4-(2-acetoxyethoxy)-2-chlorobenzoic acid
  参考文献：
  名称：

  UREA DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE OF THESE

  摘要：

  以下一般公式（I）所代表的尿素衍生物，具有V2受体的激动作用，可用作治疗或预防尿崩症、夜尿、夜间遗尿、膀胱过度活动等药物。在公式中，R1代表氢原子或可能具有取代基团的C1-6烷基；R2是氢原子或C1-6烷基；R3是氢原子、C1-6烷基或其他基团；R4、R5和R6独立地是氢原子、卤素原子或其他基团；R7是氢原子、可能具有取代基团的杂环烷基、C3-8环烷基、可能具有取代基团的氨基或可能具有取代基团的C1-6烷氧基；M1是单键、C1-4烷基或其他基团；Y是N或CRF（在公式中，RF代表氢原子、C1-6烷基或其他基团），或其药学上可接受的盐、前药、包含相同成分的药物组合物及其药用。

  公开号：

  EP1867639A1

文献信息

• New compounds and their application
  申请人：Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo

  公开号：US04855482A1

  公开（公告）日：1989-08-08

  The present invention provides a novel bis(phenoxymethyl)benzene derivative or bis(naphthoxymethyl)benzene derivative, which improves the stability of image on a heat sensitive recording paper composed of a leuco dye and a developer.

  本发明提供了一种新颖的双(苯氧甲基)苯衍生物或双(萘氧甲基)苯衍生物，可以提高由变色染料和显影剂组成的热敏感记录纸上图像的稳定性。
• Urea derivative, medicinal composition containing the same, and medicinal use of these
  申请人：Suzuki Ritsu

  公开号：US20080161294A1

  公开（公告）日：2008-07-03

  Urea derivatives represented by the following general formula (I): which have an agonism of V2 receptor, are useful as agents for the treatment or prevention of diabetes insipidus, nocturia, nocturnal enuresis, overactive bladder or the like. In the formula, R 1 represents a hydrogen atom or a C 1-6 alkyl group which may have a substituent, R 2 is a hydrogen atom or a C 1-6 alkyl group, R 3 is a hydrogen atom, a C 1-6 alkyl group or the like, R 4 , R 5 and R 6 are independently a hydrogen atom, a halogen atom or the like, R 7 is a hydrogen atom, a heteroaryl group which may have a substituent, a C 3-8 cycloalkyl group, an amino group which may have a substituent or a C 1-6 alkoxy group which may have a substituted group, M 1 is a single bond, a C 1-4 alkylene group or the like, Y is N or CR F (in the formula, and R F represents a hydrogen atom, a C 1-6 alkyl group or the like, or pharmaceutically acceptable salts thereof, or prodrugs thereof, or pharmaceutical compositions comprising the same and pharmaceutical uses thereof.

  以下通式（I）所表示的尿素衍生物具有V2受体激动剂作用，可用于治疗或预防尿崩症、夜尿症、夜间遗尿、过度活动膀胱等疾病。在该通式中，R1表示氢原子或C1-6烷基，可以有取代基；R2表示氢原子或C1-6烷基；R3表示氢原子、C1-6烷基或类似物；R4、R5和R6独立地表示氢原子、卤素原子或类似物；R7表示氢原子、可以有取代基的杂环芳基、C3-8环烷基、可以有取代基的氨基或可以有取代基的C1-6烷氧基；M1表示单键、C1-4烷基等；Y表示N或CRF（在该式中，RF表示氢原子、C1-6烷基或类似物）；以及其药学上可接受的盐、前药或包含它们的制剂，以及其医药用途。
• New substituted azetidinones as anti-inflammatory and antidegenerative agents
  申请人：MERCK & CO. INC.

  公开号：EP0481671A1

  公开（公告）日：1992-04-22

  New substituted azetidinones of the general formula (A') which have been found to be potent elastase inhibitors and thereby useful anti-inflammatory and antidegenerative agents are described.

  本文描述了通式（A'）的新取代氮杂环丁酮，发现它们是有效的弹性蛋白酶抑制剂，因此是有用的抗炎和抗退行性药物。
• Liquid crystal composition, liquid crystal element, reflective display material, and light-controlling material
  申请人：Takaku Koji

  公开号：US20070278449A1

  公开（公告）日：2007-12-06

  The present invention provides a dual frequency addressable smectic A liquid crystal composition having a crossover frequency, wherein the smectic A phase is induced by mixing of at least a first nematic liquid crystal compound or composition and a second nematic liquid crystal compound or composition.
• LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL ELEMENT, REFLECTIVE DISPLAY MATERIAL, LIGHT-CONTROLLING MATERIAL, AND METHOD OF PREPARING LIQUID CRYSTAL COMPOSITION
  申请人：Takaku Koji

  公开号：US20080292817A1

  公开（公告）日：2008-11-27

  The present invention provides a liquid crystal composition having at least a liquid crystal and a chiral dopant, in which the chiral dopant is a compound having a liquid crystalline group of a specific structure bonded to a rigid optically active compound. The present invention provides a liquid crystal element having at least a pair of electrodes in which at least one of the electrodes is a transparent electrode, and a liquid crystal layer containing the liquid crystal composition. The present invention also provides a reflective display material and a light-controlling material having at least the liquid crystal element, and a method of preparing the liquid crystal element by adding the chiral dopant to a host liquid crystal.